Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Mark H. O'Hara, MD
Advertisement
Articles by Mark H. O'Hara, MD
Advertisement
Latest Updated Articles
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic AdenocarcinomaPublished: April 4th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
2
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
3
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
4
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
5
